Lördag 21 December | 17:58:52 Europe / Stockholm

Kalender

Tid*
2025-11-06 07:00 Kvartalsrapport 2025-Q3
2025-08-14 07:00 Kvartalsrapport 2025-Q2
2025-05-08 07:00 Kvartalsrapport 2025-Q1
2025-02-20 18:00 Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-16 - Kvartalsrapport 2024-Q1
2024-03-21 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2024-03-20 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-03-30 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2023-03-29 - Årsstämma
2023-03-02 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-11 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-05-09 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2022-04-06 - Årsstämma
2022-03-10 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-12 - Kvartalsrapport 2021-Q2
2021-05-12 - Kvartalsrapport 2021-Q1
2021-04-16 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2021-04-15 - Årsstämma
2021-03-11 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-13 - Kvartalsrapport 2020-Q2
2020-05-14 - Kvartalsrapport 2020-Q1
2020-04-03 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2020-04-02 - Årsstämma
2020-03-12 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-15 - Kvartalsrapport 2019-Q2
2019-05-16 - Kvartalsrapport 2019-Q1
2019-04-05 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2019-04-04 - Årsstämma
2019-03-07 - Bokslutskommuniké 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-16 - Kvartalsrapport 2018-Q2
2018-05-16 - Kvartalsrapport 2018-Q1
2018-04-20 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2018-04-19 - Årsstämma
2018-03-07 - Bokslutskommuniké 2017
2017-11-08 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-17 - Kvartalsrapport 2017-Q1
2017-04-06 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2017-04-05 - Årsstämma
2017-03-15 - Bokslutskommuniké 2016
2016-11-09 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-18 - Kvartalsrapport 2016-Q1
2016-04-20 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2016-04-19 - Årsstämma
2016-03-16 - Bokslutskommuniké 2015
2015-11-05 - Kvartalsrapport 2015-Q3
2015-08-28 - Kvartalsrapport 2015-Q2
2015-05-22 - Kvartalsrapport 2015-Q1
2015-04-22 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2015-04-21 - Årsstämma
2015-03-12 - Bokslutskommuniké 2014
2014-11-07 - Kvartalsrapport 2014-Q3
2014-08-21 - Kvartalsrapport 2014-Q2
2014-05-06 - Kapitalmarknadsdag 2014
2014-04-29 - Årsstämma
2014-04-29 - Kvartalsrapport 2014-Q1
2014-03-21 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2014-03-20 - Bokslutskommuniké 2013
2013-11-15 - Kvartalsrapport 2013-Q3
2013-08-29 - Kvartalsrapport 2013-Q2
2013-05-15 - Kvartalsrapport 2013-Q1
2013-04-30 - Årsstämma
2013-04-30 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2013-03-14 - Bokslutskommuniké 2012
2012-11-29 - Kapitalmarknadsdag 2012
2012-04-26 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2012-04-25 - Årsstämma
2011-11-17 - Kvartalsrapport 2011-Q3
2011-10-25 - Kapitalmarknadsdag 2011
2011-08-18 - Kvartalsrapport 2011-Q2
2011-05-12 - Kvartalsrapport 2011-Q1
2011-04-29 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2011-04-28 - Årsstämma

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Zealand Pharma är verksamt inom bioteknik. Särskilt fokus återfinns inom utvecklingen av läkemedel för behandling av diabetes och diverse tarmsjukdomar. Bolaget innehar en varierad produktportfölj med separata varumärken som säljs på global nivå. Störst verksamhet finns inom den nordiska marknaden. Zealand Pharma grundades 1997 och har sitt huvudkontor i Söborg, Danmark.
2024-03-21 18:00:00

Company announcement – No. 18 / 2024

Zealand Pharma major shareholder announcement: Van Herk Investments

Copenhagen, Denmark, 21 March 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 21 March 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:

As of 20 March 2024, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 6,269,968 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 10.01% of the total share capital and total voting rights Zealand Pharma A/S.

Van Herk Investments B.V. is 100% owned by Van Herk Investments THI B.V. which is 100% owned by Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543, which is ultimately owned and controlled by Mr. Adrianus van Herk.

Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally 6,269,968 shares (each share carrying one vote), corresponding to 10.01% of the total share capital and total voting rights in Zealand Pharma A/S.

Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk.

Please see further details in the attached notification forms.

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand has a team in the U.S. For information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

Contact:

 
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
akrassowska@zealandpharma.com